

**Supplementary Table 4.** Evaluation of steatosis using attenuation coefficient and controlled attenuation parameters in patients with BMI equal to or greater than 25 (n=47)

|  | ≥S1 (≥5% steatosis) | ≥S2 (≥34% steatosis) | ≥S3 (≥67% steatosis) |
|--|---------------------|----------------------|----------------------|
| Attenuation coefficient from ATI         |                     |                      |                      |
| AUROC (95% CI)                           | 0.92 (0.81–0.98)    | 0.88 (0.75–0.96)     | 0.87 (0.74–0.95)     |
| Prevalence (n)                           | 38                  | 17                   | 3                    |
| Cutoff (dB/cm/MHz)                       | 0.62                | 0.69                 | 0.78                 |
| Sensitivity                              | 0.84 (32/38)        | 0.88 (15/17)         | 1.00 (3/3)           |
| Specificity                              | 1.00 (9/9)          | 0.73 (22/30)         | 0.80 (35/44)         |
| PPV                                      | 1.00 (32/32)        | 0.65 (15/23)         | 0.25 (3/12)          |
| NPV                                      | 0.60 (9/15)         | 0.92 (22/24)         | 1.00 (35/35)         |
| Controlled attenuation parameter from TE |                     |                      |                      |
| AUROC (95% CI)                           | 0.94 (0.82–0.99)    | 0.86 (0.73–0.94)     | 0.80 (0.66–0.90)     |
| Prevalence (n)                           | 38                  | 17                   | 3                    |
| Cutoff (dB/m)                            | 240                 | 285                  | 294                  |
| Sensitivity                              | 0.92 (35/38)        | 0.88 (15/17)         | 1.00 (3/3)           |
| Specificity                              | 1.00 (9/9)          | 0.77 (23/30)         | 0.61 (27/44)         |
| PPV                                      | 1.00 (35/35)        | 0.68 (15/22)         | 0.15 (3/20)          |
| NPV                                      | 0.75 (9/12)         | 0.92 (23/25)         | 1.00 (27/27)         |

BMI, body mass index; ATI, attenuation imaging; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; TE, transient elastography.

**Supplementary Table 5.** Patient characteristics according to the stage of liver fibrosis

|                                      | F0 (n=63)        | F1 (n=25)         | F2 (n=5)         | F3 (n=7)          | F4 (n=5)         |
|--------------------------------------|------------------|-------------------|------------------|-------------------|------------------|
| Age (year)                           | 31.0 (25.0–38.0) | 44.0 (27.8–51.5)  | 62.0 (47.5–66.5) | 63.0 (53.3–66.8)  | 63.0 (57.8–69.8) |
| Sex (male:female)                    | 32:31            | 12:13             | 2:3              | 5:2               | 2:3              |
| Body mass index (kg/m <sup>2</sup> ) | 23.3 (20.9–26.2) | 25.4 (23.6–31.2)  | 25.2 (22.2–29.4) | 26.9 (24.8–28.9)  | 27.3 (25.1–28.2) |
| Hypertension                         | 14               | 6                 | 2                | 4                 | 5                |
| Diabetes mellitus                    | 0                | 7                 | 4                | 5                 | 4                |
| ALT (IU/L)                           | 14.0 (9.0–19.8)  | 75.0 (42.8–124.0) | 32.0 (19.0–64.0) | 73.0 (47.0–112.0) | 28.0 (26.0–79.8) |
| AST (IU/L)                           | 18.0 (15.0–21.8) | 54.0 (26.0–96.0)  | 50.0 (26.3–85.0) | 60.0 (52.3–65.5)  | 42.0 (27.3–56.5) |
| Albumin (mg/dL)                      | 4.3 (4.1–4.5)    | 4.4 (4.0–4.6)     | 3.6 (2.7–3.7)    | 4.3 (4.1–4.5)     | 4.0 (3.6–4.2)    |
| Total bilirubin (mg/dL)              | 0.6 (0.5–0.9)    | 0.6 (0.4–1.1)     | 0.8 (0.4–1.4)    | 0.6 (0.4–0.6)     | 0.5 (0.4–0.7)    |
| PT-INR                               | 1.02 (0.97–1.06) | 1.01 (0.99–1.08)  | 1.12 (1.01–1.30) | 0.98 (0.96–1.00)  | 1.01 (0.98–1.17) |

Values are presented as median (IQR) or number (%).

IQR, interquartile range; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT-INR, prothrombin time international normalized ratio.